Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
48 participants
INTERVENTIONAL
2018-09-20
2019-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antenatal Betamethasone Compared to Dexamethasone - "BETACODE TRIAL"
NCT00418353
Effect of Pre-delivery Dexamethasone in Comparison With Betamethasone on Fetal Heart Trace
NCT07078786
Dose Reduction of Antenatal Betamethasone Given to Prevent the Neonatal Complications Associated With Very Preterm Birth
NCT02897076
Dexamethasone and Pregnancy: Maternal Effects
NCT06259994
A Clinical Pharmacological Study of Dose Halving of Dexamethasone in Pregnant Women With Preterm Labour With Preterm Birth at Greater Than or Equal to 34 Gestational Weeks (34GW+)
NCT06350565
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatments A & B (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
Dexamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)
Betamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)
Treatments B & A (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product B will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product A will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
(Treatment B: Betamethasone phosphate solution intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
(Treatment A: Dexamethasone sodium phosphate intramuscular injection, 4mg/mL - Total dose: 1.5mL (6mg))
Dexamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)
Betamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)
Treatments C & D (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose: 1mL (6mg))
(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)
Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Treatments D & C (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
(Treatment C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg))
Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)
Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Treatments E & D (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Treatments D & E (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product D will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
(Treatment D: Dexamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
(Treatment E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg))
Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Treatments C & E (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)
E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)
Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)
Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Treatments E & C (6 subjects)
After overnight fasting of at least 10 hours, a single dose of investigational product E will be administered orally with 240± 2mL of water in sitting posture at room temperature to each subject in this arm.
Following washout period of between 9-12 days and after overnight fasting of at least 10 hours, a single dose of investigational product C will be administered intramuscularly at gluteal or thigh region to each subject in this arm.
E: Betamethasone phosphate 0.5mg oral tablets - Total dose: 12 tablets (6mg)
C: Celestone Soluspan intramuscular injection, 6mg/mL (3mg phosphate and 3 mg acetate salts) - Total dose 1mL (6mg)
Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)
Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dexamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)
Betamethasone 4 mg/ml
Intramuscular. Total dose: 1.5 mL (6 mg)
Celestone Soluspan 6Mg/Ml Suspension for Injection
Intramuscular. Total dose: 1 mL (6 mg)
Dexamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Betamethasone Oral Tablet
Oral. Total dose: 12 Tablets (6 mg)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \- Weight not less than 45 kg.
3. \- BMI \[18.00 to 25.00 kg/m2\] \[both inclusive\].
4. \- Willingness to provide written informed consent to participate in the study.
5. \- Without any medical or surgical condition that might interfere with gastrointestinal absorption of the study drug.
6. \- Free of significant diseases or clinically significant abnormal findings during screening, medical history, physical examination, laboratory evaluations, 12-lead ECG, Chest X-ray \[PA view\].
7. \- Subjects should be non-smoker or moderate smokers (less than 10 cigarettes a day), and should not be consuming tobacco containing products \[ defined as someone who has stopped smoking for a year from the date of screening\].
8. \- Subject must be either a non-drinker or an occasional drinker of alcohol and agreed to abstain from alcoholic consumption during the study duration.
9. \- Absence of disease markers of HIV I and 2, Hepatitis Band C and Syphilis.
10. \- Female subjects of childbearing potential must be using two acceptable methods of contraception, ( e.g., intra-uterine device (IUD) plus condom, spermicidal gel plus condom, diaphragm plus condom, progestin only implants and long acting injectables (Depo Provera), etc.). These measures are required during the study and for at least two weeks after the last dose and conveyed during the inform consent process (or) postmenopausal women for at least 1 year or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy have been performed).
11. \- Subject should be literate.
Exclusion Criteria
2. \- History or presence of significant:
* Asthma, urticaria or other allergic type reactions or hypersensitivity after taking Dexamethasone or Betamethasone or any other drug.
* Ulceration or history of gastric and / or duodenal ulcer.
* Stomach or intestinal bleeding.
* Jaundice in the past 6 months.
3. \- History of drug abuse.
4. \- History of renal impairment or severe hepatic impairment.
5. \- History or presence of psychiatric disorders
6. \- Have donated 500 mL or more blood within 90 days before receiving the first dose of study drug.
7. \- Major illness during 3 months before screening.
8. \- Subjects who have participated in another clinical study in the past 3 months prior to commencement of this study.
9. \- Any difficulty in accessibility of forearm veins for cannulation or blood sampling and or difficulty with donating blood.
10. \- Refuse to abstain from food for at least 10 h prior to dosing and for at least 4 h after dosing in each period and for at least 10 h before and at least 4 h after collecting the baseline assessment blood sample in Period 1.
11. \- Refuse to abstain from fluid for at least 1 h before and 1 h after dosing.
12. \- Refuse to abstain from alcohol for the duration of the study.
13. \- Positive during breath alcohol test.
14. \- Positive during urine drug screening.
15. \- History of difficulty in swallowing study formulations.
16. \- Received any medication \[including over-the-counter products, vitamins, herbal products\] for 14 days preceding the study.
17. \- Use of enzyme modifying drugs, MAO inhibitors within 30 days prior to receiving the first dose of study medication.
18. \- History of dehydration from diarrhea, vomiting or any other reason within a period of 24 hours prior to study check-in of each period.
19. \- Consumption of xanthine containing food and beverages (chocolates, tea, coffee or cola drinks) for at least 48 hours prior to study check-in.
20. \- Consumption of grapefruit juice within the 7-days prior to study check-in.
21. \- Pregnant females as determined by positive test for pregnancy.
22. \- Lactating females.
23. \- Investigator/physician feels that it is not in the subject's and/or study's best interest to enroll the subject.
18 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bill and Melinda Gates Foundation
OTHER
Syngene
INDUSTRY
Children's Hospital Medical Center, Cincinnati
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alan Jobe, MD, Ph.D
Role: STUDY_DIRECTOR
Children's Hospital Medical Center, Cincinnati
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Syngene International Limited, Tower I
Bangalore, , India
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CIN001 - India Steroids
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.